chicago2o1o - aatod aatod... · chicago2o1o october 23 –27, ... 1 :30 a. m– 245 pc l os i ng p...

NATIONAL CONFERENCE

www.aatod.org

CHICAGO 2O1OOCTOBER 23–27, 2010Hilton Chicago • Chicago, Illinois

REGISTERBY

September 17, 2010TOTAKEADVANTAGE

OFPRE-REGISTRATIONDISCOUNT

Conference RegistrationBuilding

Partnerships:Advancing

Treatment &Recovery

BuildingPartnerships:

AdvancingTreatment &

Recovery

LETTER FROM THE CONFERENCE CHAIR

BuildingPartnerships:AdvancingTreatment &Recovery

ConferenceAt-a-GlanceAll events and times listedare subject to change.

Dear Colleagues, Patients, Advocates, Stakeholders and Friends:

On behalf of the American Association for the Treatment of OpioidDependence, Inc. (AATOD), and our hosts the Illinois State Division ofAlcoholism and Substance Abuse (DASA) and the Illinois Associationfor Medication Assisted Addiction Treatment (IAMAAT), it is mypleasure to invite you to the 2010 AATOD Conference. The conferencewill convene October 23–27, 2010 at the Hilton Chicago.

This year’s conference promises to follow in the long tradition of AATODConferences being the definitive training event for medication-assistedtreatment providers, public policy makers and advocates from all overthe world. This year, our planning committee has prepared five days ofexciting, creative and critical programming. Our conference theme,Building Partnerships: Advancing Treatment & Recovery is woventhroughout the Plenary Sessions, Workshops, Posters, Hot Topic Round-tables, and other conference activities.

AATOD has a history of dedication to providing an outstanding confer-ence experience teeming with opportunities that will help cliniciansdeliver quality care with dignity and respect to patients, while providinga forum for discussion and debate on the challenges that face programs,policy makers, advocates and patients. We have selected workshops,posters and hot topics that will encourage you to discuss your ideas,enlighten you on exciting and innovative projects promoting collabora-tion and continue to address the special needs of the medication-assisted treatment system. Pre-Conference sessions will provide morein-depth focus on stigma, risk and advocacy and provide basic knowl-edge for new practitioners. The elegant Awards Banquet will honorthose dedicated individuals who have made significant contributionsand highlight why our field is so special.

From the open AATOD Board Meeting on Saturday, October 23, 2010 tothe Closing Plenary session on Wednesday, October 27, 2010, you will bean active participant in the dynamic conference schedule. Our planningcommittees have worked diligently to ensure a diverse and fascinatingprogram. The exhibit booths will acquaint you with the latest in tech-nology, science and products that support our work. The Pre-Conferenceactivities, Welcome Reception, breakfasts and refreshments breaksallow for more informal discussions with colleagues, presenters,exhibitors, and state and federal officials.

Chicago is a friendly and beautiful city, especially in the autumn.Our Hospitality Committee has worked hard to assure that you enjoyyourself at the conference. I encourage you to register now and startplanning for a great time with your colleagues in October.

With warm regards,

Susan McKnight, MPH2010 Conference Chair

SATURDAY,10/23

7:00 a.m.–5:00 p.m. Registration Open

8:00 a.m.–5:00 p.m. The Certified Medication Assisted Treatment Advocate (CMA) Training Course

8:30 a.m.–5:00 p.m. Performance Improvement in Opioid Treatment Programs (maximum 50 participants)

8:30 a.m.–5:00 p.m. Assessment and Treatment Planning Workshop (maximum 50 participants)

9:00 a.m.–4:00 p.m. Clinical Supervision in Opioid Treatment Programs & Professional Development of the Treatment Providers

5:00 p.m.–8:30 p.m. AATOD Open Board Meeting

SUNDAY,10/24


8:00 a.m.–5:30 p.m. Opioid Maintenance Pharmacotherapy: A Course for Clinicians

8:30 a.m.–5:00 p.m. Partnership Development for OTPs

8:30 a.m.–12:30 p.m. Buprenorphine for Nurses

8:30 a.m.–12:30 p.m. Countering Opioid Stigma: Communicating Messages to Influence Public Perception

9:00 a.m.–12:00 p.m. Opioid Treatment Program Accreditation–Town Hall Meeting

9:00 a.m.–5:30 p.m. NIATx OTP Project (invitation only)

9:30 a.m.–12:00 p.m. HIV Testing, Counseling & Treatment in OTPs–New Research Findings and Clinical Implications

1:00 p.m.–5:00 p.m. Minimize Liability, Manage Risk, Ensure Patient Safety: Effective Strategies in OutpatientMethadone Treatment

1:00 p.m.–5:00 p.m. European Opiate Addiction Treatment Association (EUROPAD)

5:30 p.m.–7:30 p.m. Welcome Reception

7:30 p.m.–8:30 p.m. Methadone Anonymous Meeting (Open)

MONDAY,)0/25


7:30 a.m.–8:30 a.m. Continental Breakfast in Exhibit Hall

7:30 a.m.–9:30 a.m. Exhibits

7:30 a.m.–4:30 p.m. Posters in Exhibit Hall (Exhibit Hall closed 9:30 a.m.–11:30 a.m.)

8:45 a.m.–10:15 a.m. Opening Plenary Session—Building Partnerships: Advancing Treatment & Recovery

10:30 a.m.–12:00 p.m. Workshop Sessions

11:30 a.m.–4:30 p.m. Exhibits

12:00 p.m.–1:30 p.m. Lunch (on your own)

1:30 p.m.–3:00 p.m. Workshop Sessions / Hot Topic Roundtables

3:00 p.m.–4:00 p.m. Exhibitors Networking Refreshment Break in Exhibit Hall

4:00 p.m.–5:30 p.m. Workshop Sessions

6:00 p.m.–8:00 p.m. Digital Access to Medication (D-ATM) Town Hall: Using Technology in Opioid Treatment to Prepare forDisasters & Prevent Service Discontinuity


TUESDAY,10/26


7:30 a.m.–8:30 a.m. Continental Breakfast in Exhibit Hall

7:30 a.m.–8:45 a.m. Poster Author Session

7:30 a.m.–1:30 p.m. Exhibits

7:30 a.m.–1:30 p.m. Posters in Exhibit Hall

8:45 a.m.–10:15 a.m. Middle Plenary Session—Addiction, Pharmacology and the Criminal Justice System

10:30 a.m.–12:00 p.m. Workshop Sessions

12:00 p.m.–1:30 p.m. Lunch (on your own)

1:30 p.m.–3:00 p.m. Workshop Sessions

7:00 p.m.–9:30 p.m. Awards Banquet


WEDNESDAY,10/27


7:00 a.m.–8:00 a.m. Continental Breakfast

8:00 a.m.–9:30 a.m. Workshop Sessions

9:45 a.m.–11:15 a.m. Workshop Sessions

11:30 a.m.–12:45 p.m. Closing Plenary Session—The Partnership of the Field and the Federal Government

1:00 p.m.–3:30 p.m. Clinic Tours (Sign-Up at Hospitality Table)

2 AATOD National Conference | Building Partnerships: Advancing Treatment & Recovery

8:00 a.m.–5:00 p.m.

The CertifiedMedication Assisted TreatmentAdvocate (CMA) Training CourseWalter Ginter, CMA, NAMA Recovery, New York, NY

Nicholas Reuter, MPH, SAMHSA/CSAT, Rockville, MD

Joycelyn Woods, MA, NAMA Recovery, New York, NY

Laura McNicholas, MD, University of Pennsylvania,Philadelphia, PA

Richard Weisskopf, SOTA, Division of Alcoholism andSubstance Abuse, Illinois Department of Human Services,Chicago, IL

Kerry Wolf, RN, NAMA Recovery, New York, NY

The leading advocate and recovery organization for medicationassisted treatment, the National Alliance for Medication AssistedTreatment (NAMA Recovery), has developed this training, believingthat professionals, patients and families of patients can cometogether to work for a better understanding of methadone andmedication assisted treatment. Previous trainings have shown thatparticipants – both professionals and patients – are equally empow-ered. Therefore we encourage both patients and non-patients tobecome Certified Medication Assisted Treatment Advocates (CMA).This training is designed for non-clinicians and provides a basicunderstanding of the physiology of addiction and the use of medica-tions to treat it (i.e. methadone and buprenorphine). Regulations atthe federal, state and local levels are explained in simple terms fornon-policy makers.

With these goals in mind, the course presentation is constituted asfollows:

Medication Assisted Treatment – Basic clinical information aboutmethadone and buprenorphine treatment.

Addiction & Methadone – Current science about addiction in alanguage understandable to the non-clinician.

Regulations & Accreditation – Current regulations explained bythe federal agency that oversees methadone and buprenorphinetreatment.

State Opioid Treatment Authority (SOTA) – State regulationsexplained by the SOTA provide a view of working within statesystems.

Hands On Advocacy – Basic tools to work as an advocate and how tomanage simple issues that advocates are confronted with includingeducating patients about their rights, handling grievances, legalissues and working within communities to benefit patients and treat-ment.

Advocacy and The Media – Responding to negative media in news-papers, television, movies, etc. and writing response letters andletters to the editor.

Systems Advocacy – Using advocacy to change policy and workingwithin state and federal systems to improve the rights of patients.

Certified Medication Assisted Treatment Advocate (CMA) – Whatis a Certified Medication Assisted Treatment Advocate, ethics ofadvocacy and the mechanism of certification and how it will profes-sionalize those committed to advocacy.

Participants will come away with the initial tools for basic advocacyto grow and develop into successful advocates. The course involveseight hours of rigorous training and fulfills the training requirementfor Certification as a Medication Assisted Treatment Advocate(CMA).

Candidates for certification must register with NAMA Recovery priorto the conference. There is a separate registration fee of $50.00for the pre-conference event. The fee includes all materials,2010/2011 membership in NAMA Recovery and the application forCMA. NAMA Recovery cannot guarantee a place to anyone not pre-registered.

Lunch is not provided.

Registration information is available at: www.methadone.org/regis-tration.doc. On site registration will be between 8 a.m. to 9 a.m.outside of the session room at the hotel.

Sponsored by the National Alliance for MedicationAssisted Recovery (NAMA Recovery).

Pre-Conference Sessions

Saturday, October 23, 2010

October 23–27, 2010 | Hilton Chicago, Chicago, Illinois 3

8:30 a.m.–5:00 p.m.

Performance Improvement in OpioidTreatment ProgramsBrenda Gilliam–Jones, MPA, DB Consulting, Orlando, FL

Bernhild Quintero, MA, DB Consulting, Altadena, CA

The purpose of the Performance Improvement in Opioid TreatmentWorkshop is to provide attendees with a fast-paced workshop and anintense look at performance improvement in opioid treatment. Theworkshop provides participants with the knowledge, strategies andskills to implement or revise their organizations’ performanceimprovement programs. The training includes performance improve-ment theory; discussions of best practices in the implementation ofperformance improvement programs; and interactive exercisesshowing practical applications of performance improvementprocesses, such as data collection and analysis, use of performanceimprovement committees/functions to manage the process, and theintegration of performance improvement into other organizationalfunctions.

MODULE DESCRIPTIONS

Module One: Introduction to the Workshop

The purpose of this module is to provide an overview of the workshopand create a positive environment that sets the tone for discussingand learning about performance improvement in opioid treatmentfacilities.

Module Two: What is Performance Improvement?

The goal of this module is to create a common understanding of theterms and definitions used in the field of performance improvementthat will be referenced during the workshop.

Module Three: Developing an Organizational Culture for Perform-ance Improvement

The purpose of this module is to review the type of organizationalculture required to plan and implement an effective, comprehensiveperformance improvement system.

Module Four: Using Outcome Studies in PI Programs

The goal of this module is to discuss the benefits and challenges ofexamining existing outcome studies in the opioid treatment field andexplore how to develop clinic- or program-based OTP outcomestudies.

Module Five: The 12-Step Performance Improvement Process

The purpose of this module is to facilitate, review and discuss thekey elements of an effective performance improvement process. Themodule will also include strategies for addressing some of the chal-lenges organizations encounter in performance improvementprograms including data collection and analysis, writing outcomemeasures and evaluating plan effectiveness.

Module Six: Planning to Move Forward

The purpose of this module is to bring participants together toreview lessons learned during the training, discuss how they willapply those lessons in their own organizations and develop specificaction plans to address their organization’s performance improve-ment needs.

Module Seven: Workshop Closing Activities

The purpose of this module is to summarize the day of training,review participant expectations and give participants time tocomplete their workshop evaluation forms.

For session effectiveness, participation is limited to first 50attendees who arrive for the session.

Sponsored by the Substance Abuse and MentalHealth Services Administration, Center forSubstance Abuse Treatment (SAMHSA/CSAT).


8:30 a.m.–5:00 p.m.

Assessment and Treatment PlanningWorkshopfor Opioid Treatment ProgramsRobert Johnson, MEd, Accreditation Readiness, LLC, Columbia,MO

Cynthia Banfield-Weir, LICSW, Community Health Care,Chicopee, MA

The goal of the Assessment and Treatment Planning Workshop is toemphasize the rationale for and the process of assessment and treat-ment planning. This workshop will explain how to provide a clearbusiness case for assessment and treatment planning for internaland external audiences, and to develop a strategy to internalizeassessment and treatment planning as an integral part of the treat-ment process. This session provides a blueprint for assessment andtreatment planning that is primarily patient centered. Below is adescription of each module.

MODULE DESCRIPTIONS

Module One: Introduction to the Workshop

The purpose of this module is to set the tone for the workshop andcreate an open environment for the participants to learn aboutassessment and treatment planning.

Module Two: Introduction to Comprehensive Assessments

The purpose of this module is to review the levels of assessments andto explore and review the components of a comprehensive assessment.

Module Three: Writing an Interpretive/Integrated Summary

This module gives participants an opportunity to practice using thedata gathered in a comprehensive assessment to write an interpre-tive/integrated summary.

Module Four: Patient-Centered Treatment Planning

The purpose of this segment of the workshop is to address the bene-fits and challenges of patient-centered treatment planning and topractice incorporating assessment data into patient-centered treat-ment plans.

Module Five: Components and Development of Patient-CenteredTreatment Plans

The purpose of this module is to identify and review the componentsof a patient-centered treatment planning process and to provide anopportunity for the participants to use the data, knowledge and skillsacquired during the workshop to create patient-centered treatmentplans.

Module Six: Putting It All Together

The purpose of this module is to review the connection between acomprehensive assessment and patient-centered treatment planning.



9:00 a.m.–4:00 p.m.

Clinical Supervision and Professional Developmentof the Substance Abuse CounselorLive Supervision for the Clinical Supervisor

Richard Gelb, New York, NY

The goal of this workshop is to provide a practical understandingof—and professional competency in—the clinical supervisionprocess using an in-depth study and analysis of clinical supervisioncase presentations. This seminar will use material from workshopparticipant’s supervisory sessions to demonstrate the application ofclinical supervision theory and practice. Participants will beexpected to present portions/segments of supervisory experiences,i.e., case presentations of supervisor: supervisee clinical supervisionmeetings, for in-depth study and analysis.

Learning Objectives:

1. Enhance skills in providing clinical supervision using a case studymodel;

2. Learn different approaches for addressing and resolving super-visor: supervisee conflicts;

3. Increase understanding of key clinical supervision issues:a. supervisory alliance; b. parallel process; c. boundary problems;d. cultural and contextual factors; ethical and legal issues.

Note: Clinical Supervision Part II is for experienced and practicingclinical supervisors in the behavioral health field.




AATOD Open Board Meeting


5:00 p.m.–8:30 p.m.


8:00 a.m.–5:30 p.m.

OpioidMaintenance Pharmacotherapy:A Course for CliniciansLaura McNicholas, MD, Philadelphia Veterans AdministrationMedical Center, Philadelphia, PA

Susan Neshin, MD, JSAS Healthcare, Inc., Asbury Park, NJ

J. Thomas Payte, MD, Colonial Management Group, LP,Orlando, FL

Trusandra Taylor, MD, JEVS, Human Services, Philadelphia, PA

This course is recommended for clinicians with experience and/orinterest in the medication-assisted treatment of opioid dependence.This program provides basic and state of the art information. Thecurriculum is updated to include current consensus guidance forbest practice treatment for opioid addiction. Topics include overviewof opioid dependence, epidemiology, opioid pharmacology/neurobi-ology; evidence-based treatment options, patient assessment/selec-tion, special populations, induction and maintenance protocols, painmanagement, drug-to-drug interactions, adverse effects, methadonedeaths, managing medical/psychiatric problems, drug testing, regu-latory issues, an accreditation update, risk management and anoverview of buprenorphine.

Participants will receive a comprehensive syllabus with referenceand resource materials. The curriculum will include relevant casestudy discussion with audience participation to facilitate thelearning process. To further integrate the educational objectives,participants are encouraged to discuss challenging problems andclinical issues to facilitate understanding of didactic principles.

Four experienced opioid treatment program medical directors willconduct the program, focusing on the goal for participants to acquirethe essential knowledge and skills necessary to deliver safe andeffective medication-assisted treatment for patients with opioiddependence.

The $175.00 registration fee includes a morning coffee service,afternoon luncheon and the evening’s Welcome Reception.

Sponsored by the American Association for theTreatment of Opioid Dependence, Inc. in cooperationwith the American Academy of Addiction Psychiatryand the American Osteopathic Academy of AddictionMedicine.

Supported by the National Institute on Drug Abuse.

8:30 a.m.–12:30 p.m.

Countering Opioid Stigma: CommunicatingMessages to Influence Public PerceptionFrank J. Carillo, ECG, Inc., Englewood, NJ

Dan McGill, McGill Consulting, Milford, DE

Opioid treatment programs and patients have historically been thetarget of negative public opinion and adverse media coverage. Thishas affected our ability to influence national drug policy, explain thescience of opioid addiction and treatment, gain the funding neces-sary to provide quality treatment to all who require it, and ultimatelyto operate in the best interests of our patients and communities.

This workshop teaches three key messages specifically designed tocounter the stigma and stereotypes deeply embedded in the percep-tion of opioid addiction and medication-assisted treatment (MAT).These messages resulted from a year-long pilot project entitled“Communicating Messages That Achieve Results”. Providers willhear these messages and learn how to communicate them in order tocreate a positive impact within their communities. The workshopwill include Q & A techniques designed to deal with emotionallycharged audiences while reinforcing the presenter’s objective. MATadvocates using this approach have been very successful, henceanother chance to experience this training!

Sponsored by the American Association for theTreatment of Opioid Dependence, Inc.

Supported by VistaPharm, Inc.


Sunday, October 24, 2010


8:30 a.m.–5:00 p.m.

Partnership Development for OTPsMaxine Fuller, MS, McKinley Group, Inc., Sandy Springs, GA

Partnership development is a strategy that many organizations areusing to enhance their ability to design, fund and provide services.The one-day Partnership Development for Opioid TreatmentPrograms Workshop will provide participants with the skills andtools necessary to identify, recruit and maintain effective partner-ships. This is a hands-on and interactive workshop that will allow theparticipants to leave with a partnership development plan and effec-tive implementation strategies and resources.

In addition to the objectives stated above, completion of this work-shop will enable participants to:

• Determine if partnering is the correct strategy for their organiza-tions

• Identify partnership implementation tools and resources

The topics the workshop will cover include:

• Benefits and Challenges of Partnering

• Partnership Assessment Exercise

• Partners



9:00 a.m.–12:00 p.m.

Opioid Treatment ProgramAccreditation—TownHallMeetingMegan Marx, MPA, The Joint Commission, Oakbrook Terrace, IL

Mary Cesare-Murphy, PhD, The Joint Commission, OakbrookTerrace, IL

This session will provide Joint Commission accredited organizationswith an update on changes/revisions planned for accreditation stan-dards and elements of performance in the Comprehensive Accredita-tion Manual for Behavioral Health Care (CAMBHC). The JointCommission has recently completed a standards improvement initia-tive aimed at streamlining standards and elements of performance,and tailoring the survey process. A review of these changes, as wellas a review of changes made to the format and structure of theCAMBHC electronically, to more effectively utilize the manual intheir quality improvement processes and their continuous accredita-tion readiness efforts will be discussed.

We also intend to have our OTP account representatives and stan-dards interpretation staff available during this session to meet withthe organizations face-to-face and provide feedback to them aboutthe survey application process and standards interpretation. Weintend to use a Q&A format for this part of the session, afterproviding participants with background information about the rolesand responsibilities these two work groups represent.

The two speakers will share time equally during the presentation.The account representatives and the standards interpretation staffmember will participate during the last 30–45 minutes of the presen-tation, as needed.

Sponsored by The Joint Commission.

8:30 a.m.–12:30 p.m.

Buprenorphine for NursesColleen LaBelle, RN, Boston Medical Center, Boston, MA

Sara Azimi-Bolourian, MSN, SAMHSA, Rockville, MD

This Pre-Conference session introduces a new guideline titled“Buprenorphine: A Guide for Nurses”. It was published by theSubstance Abuse and Mental Health Services Administration(SAMHSA) as the 30th publication in the Technical Assistant Publi-cation Series (TAP #30). This Pre-Conference session is intended toprovide nurses with general information about buprenorphine prod-ucts—Suboxone® (buprenorphine and naloxone) and Subutex®

(buprenorphine)—for the pharmacological treatment of opioidaddiction. It covers screening, assessment, and diagnosis of opioiddependence and its associated problems and contains detailedprotocols for the use of buprenorphine under a variety of clinicalscenarios, including the use of buprenorphine with patients who areexperiencing co-occurring pain or psychiatric disorders, or chemicaldependency involving more than one substance.

The session also provides nurses with a comprehensive overview ofnursing roles in screening and assessing the health status of patientswho have addiction problems. Moreover, the session focuses onnurses instrumental roles in the development and ongoing moni-toring of treatment plans for patients who are on buprenorphinetreatment and counseling and referral for psychosocial treatment.This session will assist nurses in developing improved understandingof the complexities of addictions treatment, and will promote bettertreatment outcomes by utilizing a team approach to patients’ opioiddependence.

Sara Azimi-Bolourian will provide introductory remarks and a briefoverview of the federal requirements for buprenorphine prescriptionand nursing roles.




Colleen LaBelle will lead the session afterwards and provide infor-mation on the pharmacology of buprenorphine, detailed protocolsfor the use of buprenorphine under a variety of clinical scenarios,and protocols on the use of buprenorphine for medically supervisedwithdrawal, for classifications of medically supervised withdrawal,and for maintenance treatment. She will also describe the advan-tages and challenges of providing office-based treatment.


9:00 a.m.–5:30 p.m.

NIATx OTPProject (invitation only)

Kimberly Johnson, MBA, University of Wisconsin, Madison, WI

Lynn Madden, MPA, APT, New Haven, CT

Tom Zastowny, PhD, Webster, NY

This session will be the wrap up session for the CSAT funded NIATxOTP project. The project is a year-long effort for 30 providers toimprove access to and retention in treatment. The goal of the daywill be to celebrate success, share stories and learn some tools andtechniques for spreading improvements through the agency whenthere are multiple sites and sustaining improvement over time oncethe project is complete.

It will begin with an overview of the project accomplishments,followed by participant presentations. Prior to lunch there will be apresentation on spreading change. Following lunch there will bemore participant presentations and the program will wrap up with afinal presentation on sustaining improvement.

9:00: Project Accomplishments: Kim Johnson

9:30: Participant Presentations: Overcoming our Biggest Barriers

11:00: Spreading Change through the Agency: Tom Zastowny

12:00: Lunch

1:00: Participant Presentations:How I Got the Staff Motivated for Change

2:30: Break

3:00: Sustaining Change: Lynn Madden

4:30: Wrap up and Plan for Conference Presentation

The participant presentation topics are subject to change based onthe progress of the overall project and their identification of issuesthey would like to hear about from their peers .

9:30 a.m.–12:00 p.m.

HIV Testing, Counseling and Treatment in OTPs—NewResearch Findings and Clinical ImplicationsPetra Jacobs, MD, Center for the Clinical Trials Network,National Institute on Drug Abuse, Bethesda, MD

Lisa R. Metsch, PhD, University of Miami, Miami, FL

Katharina Wiest, PhD, CODA, Inc., Portland, OR

Elinore F. McCance-Katz, MD, University of California at SanFrancisco, San Francisco, CA

According to estimates from the nation’s new HIV incidence surveil-lance system, there were approximately 56,300 new cases ofHIV/AIDS diagnosed in the United States in 2006. Moreover, amongthe more than one million people living with HIV in the U.S., approx-imately one-fifth do not know they are infected. Recent studies haveshown that fewer than half of U.S. drug abuse treatment programsare currently offering HIV testing on-site to their patients (Brown Jr.et al., 2006; Oser, Tindall, & Leukefeld, 2007; Pollack, D’Aunno, InPress; Strauss, Des Jarlais, Astone, & Vassilev, 2003).

NIDA’s Clinical Trials Network conducted a study to evaluate theeffectiveness of strategies (referral, on-site rapid testing, on-siterapid testing + counseling) to (1) increase HIV testing acceptanceand receipt of results and (2) decrease HIV sexual risk behaviors.The target population was individuals receiving drug abuse treat-ment within community-based drug abuse treatment programs inthe United States. 2,452 patients were screened in 12 drug abusetreatment programs (including three methadone programs) acrossthe U.S. to identify patients who had not been HIV tested in the past12 months. The screening data indicate that only 28% had beentested in the prior year, and one-fifth had never been tested. In thissession, the main study findings will be presented and their implica-tions for OTP practice discussed.

The last presentation will summarize the issues related to medica-tion-assisted treatment and HIV/AIDS. Drug users’ access to anti-retroviral therapy might be complicated. Additional comorbiditiesmight cause poorer outcomes for HIV/AIDS. It is important for thehealthcare provider to understand and manage the complex druginteractions that are clinically significant. The presentation willprovide a general overview and evidence-based recommendations.

Sponsored by the National Institute on Drug Abuse,the National Drug Abuse Treatment Clinical TrialsNetwork (NIDA/CTN).


1:00 p.m.–5:00 p.m.

Minimize Liability, Manage Risk, Ensure PatientSafety: Effective Strategies in OutpatientMethadone TreatmentTodd Mandell, MD, Vermont ADAP, Burlington, VT

Lisa Torres, JD, New Jersey Division of Addiction Services,Lawrenceville, NJ

Alan Wartenberg, MD, Meadows Edge Recovery Center, NorthKingstown, RI

Although the SAMHSA/CSAT Treatment Improvement Plan (TIP) 43states that medication-assisted treatment has been effective in facil-itating many patients’ recovery from opioid addiction for over 40years, recent reports of adverse incidents and deaths associated withmethadone have raised concern among state and national legislatorsabout the risks involved. The 2009 General Accountability OfficeReport examined factors contributing to methadone-associateddeaths and found that use of methadone for pain managementincreased the drug’s prevalence, contributing to the rise inmethadone-associated overdose deaths. These deaths and otheradverse incidents led to a number of lawsuits and proposed legisla-tion such as S. 754, the Methadone Treatment and Protection Actthat would have legislated clinical practice, patient safety andcommunity values.

Research supports the perspective that opioid addiction is a medicaldisorder that can be treated safely and effectively with medicationswhen they are administered under conditions consistent with theirpharmacological efficacy and accompanied by necessary supportiveservices such as psychosocial counseling, treatment for co-occurringdisorders, medical care and vocational rehabilitation. Physicians,psychiatrists, clinical staff, nurses, and opioid treatment programdirectors, providers and staff need to understand how to minimizeincidents such as patients driving under the influence of multiplesubstances, unsafe diversion of take-home medication, unsafe induc-tion and reduction of medication, and dosing practices withoutconsideration of clinically assessed severity of dependence andmetabolism rates.

This workshop is for healthcare and mental health professionalswho are involved in the direct care of patients seeking help foropioid dependence. Conducted by experts in insurance, law, policyand daily clinical practices, this training will provide a frameworkfor applying best practices and developing comprehensive riskmanagement strategies to improve patient safety and eliminatetransfer, reduce and manage the risks associated with medication-assisted treatment for opioid dependence. Participants will have theopportunity to ask questions and enter into a dialogue with facultyand each other to expand their knowledge of current trends anddevelop skills in identifying and preventing risks.


1:00 p.m.–5:00 p.m.

European Opiate Addiction Treatment Association(EUROPAD): Heroin Addiction andRelated ClinicalProblems

Medication Assisted Treatment has been available worldwide. Ouraffiliation with the European Opiate Addiction Treatment Associa-tion (EUROPAD) continues to provide us with access to the skills,knowledge and wisdom of our international colleagues. Our confer-ence provides an opportunity for some of the world’s best thinkersand practitioners to share their thoughts and perspectives.

Consistent with this spirit of international collaboration and part-nership, EUROPAD will be enlisting an expert panel of European andinternational providers and practitioners who will share their expe-riences, findings, successes and challenges in the context of theirrespective countries and cultures.

This is an open session with a broad range of topics and focus.Anyone interested in learning about how opioid treatment isprovided outside the United States, the diversity of ideas andapproaches and the impact of culture and government policies,are encouraged to attend.

In collaboration with EUROPAD-Italia and ItalianSociety of Addiction Medicine (SITD)



Welcome Reception

Sunday, October 24, 20105:30 p.m.–7:30 p.m.

The Welcome Reception affords all participants theopportunity to make new professional and personalacquaintances, as well as to enjoy some relaxing timewith old friends and colleagues not seen for too long.

Sponsored in part by Covidien-Mallinckrodt.


The National Conference serves as a central gathering point forthe opioid treatment community and offers significant opportu-nities for exhibiting companies and attendees to interact withother professionals who are devoted to the treatment of opioiddependence throughout the nation and abroad. The registrantswill consist of the decision makers in this field who spend over$1 billion annually treating more than 260,000 patients in opioidtreatment programs. In order to provide exhibitors with steadyexposure to conference attendees, all continental breakfasts,refreshment breaks and poster sessions will be held exclusivelyin the exhibit area. An Exhibitors Networking RefreshmentEvent will be held Monday, October 25th from 3:00–4:00 p.m.to encourage contact and dialogue between opioid treatmentprofessionals and the exhibiting companies.

Exhibit HoursMonday, October 25: 7:30 a.m.–9:30 a.m.; 11:30 a.m.–4:30 p.m.Tuesday, October 26: 7:30 a.m.–1:30 p.m.

Posters are in place at all times when the exhibit hall is open—Authors will present their topic on Tuesday from 7:30 a.m.–8:45 a.m.

Exhibitors as of April 28, 2010

Poster Topics Include:Mobile Medication Units and Office Based Services for Opioid Addicted Patients

Opioid Treatment Program Mortality Reporting Form

Transformation through Partnerships—Evolution of Methadone Maintenance in the 21stCentury

HIV/AIDS-Related Health Services in Substance Abuse Treatment Programs

Opiate Addiction Treatment Patients and Chronic Pain—How Data Can Help Improve Practice

Social Networking Media and OTPs—Opportunities to Improve Communication and TreatmentOutcome

Comparison of a Prescription Based Outpatient Buprenorphine Program with a DispensedBuprenorphine Program in a Community Setting

Sex and Drug Using Behaviors Among HIV+ African Americans and Hispanics in an OTP

Massachusetts Home Detoxification Model—An Integration of Public Health and Primary Care

Office-Based Pharmacy-Based Program—A Novel Medical Maintenance Model for OAT in NewYork City

Methadone Maintenance Treatment Patients Characterized with High Rate of ADHD and OCDand Low Rate of Pathological Gambling

SMS (Social and Health Service)—Make the Link Inside Outside!

Prescription Opioid Abuse and Other Factors Associated with First Time Admission into anOpioid Treatment Program

Needle Exchange in Prison—Two-Thirds of the Jailhouse Medical Units Are Ready in France!Preliminary Results of the National Harm Reduction Survey

Implementation of an Electronic Information System to Enhance Practice at an OpioidTreatment Program

Program Development and Patient Characteristics Associated with Overdose PreventionEducation and Training Within Opioid Dependence Treatment Programs

Safe Methadone Induction / Stabilization—A Best Practice Approach to Improve PatientAwareness and Knowledge

Partnerships—A Vocational Perspective

The Effect of a Telephonic Patient Support Program on Treatment for Opioid Dependence—Outcomes At One Year

Improving Access to Buprenorphine Services

Opioid Addiction Treatment Modalities in the Ukraine

Medication Assisted Recovery with Vivitrol for Poly-Substance Dependence—Case Series from2006-2010

Sublingual Buprenorphine Treatment of Opioid Dependence in American Indians

A Longitudinal Analysis of the Effect of Buprenorphine-Medication Assisted Treatment(B-Mat) and a Structured Patient Support Program on B-Mat Adherence for the Treatment ofOpioid Dependence

Refusal of Ancillary Support Services Early in Opioid Dependence Treatment Predicts SixMonth Buprenorphine-Medication Assisted Treatment Compliance

Opioid Relapse Rates Among a Sample of New Buprenorphine-Medication Assisted TreatmentPatients—Relationship with Medication Compliance at One Year

Maternal and Neonatal Methadone Issues—Who are We Treating

An Examination of How Abstinence/Morality-Based Narratives of Addiction Effect the Treat-ment Decisions of Opioid Dependent Individuals

Methadone Maintenance Outcomes—Quality of Life and Patient Self Esteem Examined inRelation to Anecdotal Evidence of Patients’ Desire to Discontinue Treatment

Disaster Planning and Substance Abuse Stigma with Respect to Methadone MaintenanceTreatment

Buprenorphine at Syringe Exchange

Comparison of Psychosocial Treatments added to Pharmacotherapy with Buprenorphine

Integration of Methadone Maintained Pregnant Women into Residential Care—MedicationSafety Issues

Differences in Retention by Buprenorphine Treatment Site

Exhibit and Poster Sessions

Domestic and International posters will providevaluable research findings to treatment providers.

AATOD

Ammon Analytical Laboratory Inc

Bendiner & Schlesinger Inc.

C&C Containers, LLC

Calloway Laboratories, Inc

CARF

Clinical Science Laboratory Inc.

Covidien-Mallinckrodt

Dominion Diagnostics Corp Headquarters

GlaxoSmithkline

Kols Containers/Oberk of New England

National Institute on Drug Abuse

Netalytics

Netsmart Technologies

NSM Insurance Group

Reckitt Benckiser Pharmaceuticals, Inc.

Redwood Toxicology Laboratory Inc

Roxane Laboratories, Inc.

SAMMS

San Diego Reference Laboratory

Scilog, Inc.

SMART Management Inc.

Substance Abuse and Mental Health Services Administration

The Joint Commission

Tower Systems Inc

VistaPharm Inc.


OPENING PLENARY SESSION

8:45 a.m.–10:15 a.m.

Building Partnerships:Advancing Treatment &RecoverySusan McKnight, MPH, Program Coordinator, Lake CountyHealth Department, Waukegan, IL

Mark W. Parrino, MPA, President, American Association for theTreatment of Opioid Dependence, Inc., New York, NY

Theodora Binion Taylor, Director, Division of Alcoholism andSubstance Abuse, Illinois Department of Human Services,Chicago, IL

H. Westley Clark, MD, JD, CAS, FASM, Director, Center forSubstance Abuse Treatment, Rockville, MD

Hon. Danny K. Davis, Congressman 7th District, House ofRepresentatives, Chicago, IL

The Opening Plenary will focus on the significant challenges facingour field in Illinois and the nation. Ms. Susan McKnight will open theconference by welcoming attendees to Chicago and will provide anoverview of the conference. Mr. Mark Parrino, AATOD President, willpresent an overview of the challenges facing opioid treatmentprograms in the United States and AATOD’s initiatives to respond tothese changing dynamics now and in the future. Dr. Westley Clark,Director of Center for Substance Abuse Treatment, will discussfederal initiatives to improve treatment access and quality.Conferees will also hear from Illinois’ Director of the Department ofAlcoholism and Substance Abuse (DASA), Theodora Binion Taylorand Congressman 7th District, House of Representatives, Danny K.Davis, on how the state is working to build partnerships to advancetreatment and recovery in Illinois and the nation.

10:30 a.m.–12:00 p.m.

WORKSHOP SESSIONS

Workshops will offer a chance to review the latest treatment dataand health care policies, examine their implications for our patients,and strengthen the skills needed to improve the quality of services.

Basic Track: This year we will again be offering a specialsequence of workshops designed to act as a refresher for seasonedprofessionals and to meet the needs of individuals who are new tothis field. Those who attend all six sessions listed will receive aspecial certificate of completion.Basic Track Workshop Sessions: A1, B1, C1, D1, E1 and F1

Monday Continental Breakfast sponsored byVistaPharm Inc.

Conference Sessions

Monday, October 25, 2010

A1 Methadone 201Moderator: Laura McNicholas, MD, Philadelphia VAMC,Philadelphia, PA

Trusandra Taylor, MD, JEVS Human Services, Philadelphia, PA

Susan Neshin, MD, JSAS Healthcare Inc., Metuchen, NJ

J. Thomas Payte, MD, Colonial Management Group, LP,Orlando, FL

This interactive workshop is designed for the physician/clinicianwho has taken Opioid Maintenance Pharmacotherapy: A Course forClinicians and is now treating patients in an opioid treatmentprogram. Reviews of this course showed requests for additional timeand more advanced information related to opioid addiction treat-ment. A short update on new information and ongoing researchabout methadone will be presented. Topics for discussion mayinclude: methadone associated mortality, induction issues, cardiacrisk assessment/management, drug-drug interactions, benzodi-azepines and pain management.

Participants are encouraged to bring interesting/complex cases tostimulate questions that will illustrate issues in the successfulmanagement of patients on methadone maintenance.

* Note: Basic Track

A2 Treating Opioid Dependent Pregnant Patients:Results of theMOTHERStudyHendree Jones, PhD, Research Triangle Institute International,RTP, NC

Karol Kaltenbach, PhD, Thomas Jefferson University,Philadelphia, PA

This workshop will present neonatal and maternal outcomes of theMaternal Opioid Treatment: Human Experimental Research(MOTHER) project, a seven-site, international, double-blindrandomized clinical trial. The presentation will include the compar-ison of methadone and buprenorphine on the primary outcomemeasures: number of neonates requiring NAS treatment; peak NASscore; total amount of medication needed to treat NAS; length ofhospital stay; and head circumference. Key secondary outcomespresented will include neonatal and maternal drug use treatmentand delivery outcomes. The workshop will conclude with a discussionof the historical importance and far-reaching clinical practice andhealth-policy implications of these data.

A3 NewYork’s Outpatient Transformation:Integrated OTP&General TreatmentBelinda Greenfield, PhD, NYS Office of Alcoholism & SubstanceAbuse Services (OASAS), New York, NY

Ira Marion, MA, Albert Einstein College of Medicine (AECOM),Bronx, NY

Deborah Egel, Esq., NYS Office of Alcoholism & Substance AbuseServices (OASAS), New York, NY


New York’s “Transforming Out-Patient Services” (TOPS) intends tointegrate opioid treatment, general chemical dependency treatment,and ambulatory detoxification within one continuum of outpatientcare. Services offered under this model include medication-assistedtreatment options, behavioral therapy approaches and recovery-oriented/patient centered care within a single clinical setting. Thehistorical underpinnings of this model, i.e., NYS’ Methadone Trans-formation efforts, will be presented along with the current regula-tory, clinical and certification challenges, as demonstrations of thismodel are implemented statewide.

A4 Low-Intensity Treatment Strategies:Maximizing Treatment RetentionRobert P. Schwartz, MD, Friends Research Institute, Baltimore, MD

Donald A. Calsyn, PhD, Alcohol and Drug Abuse Institute,University of Washington, Seattle, WA

Shannon Gwin Mitchell, PhD, Friends Research Institute,Baltimore, MD

Decades of research on medicated assisted opioid treatmentprograms (OTP) have consistently found that patients remaining intreatment have superior outcomes in terms of substance use, arrestsand incarceration, employment and physical health as compared tothose who leave treatment. Patients leave treatment both voluntarilyand involuntarily. In this workshop, findings from several studies willbe presented that provide practical strategies that could be imple-mented in OTPs to reduce both voluntary and involuntary treatmentterminations. Strategies include interim methadone, alternatives toadministrative discharge, and strategies to improve taperingattempts by stable patients.

A5 Integrating a Peer to Peer Recovery OrientedSystemof Care (ROSC) intoMATJoycelyn Woods, CMA, National Alliance of Medication AssistedRecovery, New York, NY

Walter Ginter, CMA, MARS Project (a NAMA Recovery project),Bronx, NY

OTPs have changed from the early model that included a Peer toPeer component and an array of comprehensive services. A RecoveryOriented System of Care (ROSC) is a comprehensive array of serv-ices that are person-centered and a self-directed approach to treat-ment and recovery. Peer to Peer services improve patient self esteemand work in a positive way so patients set goals and see themselvesas capable. ROSCs build on personal responsibility, patient strength,and resilience of individuals, family support and communities toachieve sustained health, wellness and recovery. This workshop willprovide clinics with the tools to understand and identify a ROSC andunderstand the significance of Peer to Peer services.

1:30 p.m.–3:00 p.m.

HOT TOPIC ROUNDTABLES

Hot Topic Roundtables are facilitated discussions that focus oncurrent controversial issues in an informal context. Meet with yourcolleagues as you learn, challenge, support and share your viewswith others who may have similar or different opinions, experiencesor interests. Engage in one or more of these facilitated discussions.

Experienced leaders in the field will be facilitating these sessions:• Cardiac Conduction Issues (QT Interval)• US–Mexican Border Issues• Cannabis Use in MAT• Solutions to Administrative Discharge for Financial Reasons• Benzodiazepines & Admission to OTPs• Methadone Related Drug Deaths and Policy Implications

1:30 p.m.–3:00 p.m.

WORKSHOP SESSIONS

#1 Nutrition in OTPKaren Lazarus, MD, Beth Israel Medical Center MethadoneMaintenance Treatment Program, New York, NY

Many patients in opioid treatment programs are at risk for nutrition-related diseases. Identifying and addressing malnutrition or nutri-tional risk enables us to help our patients enhance their health andwell-being. This also meets The Joint Commission standards fornutritional screening and assessment for patients in opioidtreatment.

This workshop will discuss: nutrition screening as per The JointCommission standards; identification of malnutrition; methods ofnutritional assessment with emphasis on problems commonly seenin OTPs; tools for rapid nutritional assessment; guidelines forreferral; and an overview of healthy eating focusing on healthful foodrecommendations.

#2 Overdose Prevention and Treatment in OpioidTreatment ProgramsAlexander Walley, MD, Boston University School of Medicine,Boston, MA

Melinda M. Campopiano, MD, UPMC Mercy Family MedicineResidency Program, Pittsburgh, PA

Maya Doe-Simkins, MPH, Boston Medical Center, Boston, MA

Overdose is a significant public health concern. Unintentionalpoisoning was second only to motor vehicle injuries as causes ofunintentional injury deaths in 2006. A CDC report showed thatopioid analgesics were involved in almost 40% of all poisoning deathsin 2006. Recent data from opioid treatment programs (OTPs) suggestthat overdose is an important factor in mortality of patients in treat-


ment. Evidence suggests that overdose prevention programs arefeasible and effective. OTPs are in an important position to imple-ment overdose prevention programs. This workshop is designed toimprove knowledge about opioid overdose, including risk factors,prevention, identification and management.


#3 Strategic Alliances—Clinically Effective andCost Efficient Treatment: 6 ExamplesLinda Hurley, CAGS, CODAC Behavioral Healthcare,Cranston, RI

Collaborations and partnerships can expand treatment and recoverysupport options for our increasingly challenged population. They canbe expansive and community-wide, or small and precisely defined.Developing a culture of collaboration is critical to accessing, sharingand optimizing existing resources. Six varied, successful and prac-tical models will offer participants an opportunity to develop a planto increase the quality and scope of their services through collabora-tion and partnerships. In addition to presenting blueprints forcommunity partnerships, outcome data and research, the workshopwill address the need for effective community public relations—thefoundation for successful community partnering.

4:00 p.m.–5:30 p.m.

WORKSHOP SESSIONS

B1 Meeting theNeeds of PatientswithCo-Occurring DisordersJoan E. Zweben, PhD, Executive Director, East Bay CommunityRecovery Project, Oakland, CA

This workshop will discuss how counselors can help integrate thetreatment of psychiatric disorders into the opioid treatmentprogram. The presenter will discuss addictive behavior and psychi-atric problems, barriers to addressing them, prioritization of treat-ment tasks and appropriate education for patients. The presenterwill focus on anxiety disorders (especially PTSD) and mood disor-ders, and also review screening and assessment of suicide risk fromthe perspective of agency protocols as well as the role of the coun-selor. Treatment issues will include psychosocial issues (copingstrategies, stigma), medication issues (attitudes, feelings, adher-ence), and collaboration with physicians as well as a review ofseveral evidence-based treatments.

* Note: Basic Track

B2 Prescription Opioid Addiction TreatmentStudy: Outcomes and Clinical ImplicationsRoger D. Weiss, MD, McLean Hospital, Belmont, MA

Jennifer S. Potter, PhD, University of Texas Health ScienceCenter, Department of Psychiatry, San Antonio, TX

Prescription opioid dependence has become a national public healthpriority; prescription opioids are now comparable to marijuana asthe most common form of drug initiation. This workshop will presentthe primary and secondary outcomes involving treatment responsefrom the NIDA Clinical Trials Network Prescription Opioid AddictionTreatment Study—the first multi-site randomized controlled trial tospecifically examine treatments for individuals with prescriptionopioid dependence, including those with chronic pain. The presen-ters will also discuss the clinical and scientific implications of thestudy results for the treatment of prescription opioid dependence.

B3 Methadone Safety Best Practices:Clinician and Patient EducationIvette Torres, MEd, Associate Director for Consumer Affairs,SAMHSA, CSAT, Rockville, MD

Laura McNicholas, MD, Philadelphia Veterans AdministrationMedical Center, Philadelphia, PA

Walter Ginter, CMA, National Alliance for Medication AssistedRecovery, Bronx, NY

This workshop will preview and discuss the upcoming MethadoneSafety Videos produced by the Substance Abuse and Mental HealthServices Administration. There are two short videos—one for clini-cians and one for patients. The workshop panel will lead a discussionon engaging patients and clinicians with the videos. The panel willalso discuss how to promote and educate clinicians and patients onbest practices for Opioid Treatment Programs. The workshop alsoprovides information on how to engage patients in the recoveryprocess and how to educate patients on methadone safety.


B4 Risk Reduction for Illicit BenzodiazepineAbusewithin an OTPPopulationDan Johnson, PhD, The Acadia Hospital, Bangor, ME

This presentation will address benzodiazepine abuse within opioidreplacement treatment from both a risk management and recovery-oriented perspective. Risk reduction and therapeutic engagementstrategies, and medical interventions to reduce concomitant benzo-diazepine use among patients will be discussed. From July throughDecember 2009, benzodiazepine abuse at Acadia Hospital’s replace-

Conference Sessions

Monday, October 25, 2010


ment therapy programs was reduced by slightly over 30 percent.Data from this effort related to patient replacement therapy dose,toxicology results, psychiatric treatment needs, overall stability,treatment drop rates and perceptions of care will be reviewed at 6and 9 month intervals.

B5 Spirituality and Recovery: Exploring the Valueof the Spiritual Alliance in RecoveryAlan Lee Nolan, LCSW, Connecticut Counseling Centers, Inc,Danbury, CT

With research highlighting the “therapeutic alliance” as a vital treat-ment component positively impacting a patient’s motivation forchange, a patient’s relationship, or “recovery alliance” with a “higherpower” commands clinical attention. Examining evidence regardingthe potential value of spiritual dimensions of recovery, this workshopexplores cultivating a person-centered MMTP through the utility ofintegrating a patient’s spiritual orientation. The workshop proposesa spiritually sensitive recovery archetype, and its effectual assimila-tion with dominant secular treatment models. Partnerships withcommunity-based spiritual resources, along with ongoing staffcompetency, quality improvement measures and the use of existingdata collection processes will be discussed.

6:00 p.m.–8:00 p.m.

Digital Access toMedication (D-ATM) TownHall:Using Technology in Opioid Treatment to Preparefor Disasters and Promote Continuity of CareArlene Stanton, PhD, SAMHSA/CSAT, Rockville, MD

Daksha Arora, PhD, Westat, Rockville, MD

SAMHSA’s D-ATM project (“Digital Access to Medication”) wasconceived as a technological approach to help ensure OTPs caneffectively and safely provide medication to patients who have beendisplaced from programs where they are normally enrolled. Thisgrassroots effort began following the events of 9-11, and from thebeginning, SAMHSA/CSAT has benefited from the support of AATOD,COMPA, NAMAR and a Steering Committee composed of a range ofstakeholders. A feasibility and planning study conducted early onwas followed by a smaller developmental study. This confirmed theneed for a deliberately simple, Web-based, centralized databasecontaining only the information needed by an OTP to verify patients’identity and to provide accurate and safe dosing. In 2005, SAMHSAprovided funding to develop the infrastructure for and conduct alimited pilot-test of the system in three to four major metropolitanareas. The project is now in Phase III. At this point, ‘lessons learned’from the initial pilot have been examined, processes have beenstreamlined and attention has turned to beginning implementationof the system into programs in targeted areas around the country.Over time, D-ATM has evolved from a disaster preparedness systemto an important tool to promote continuity of care in more routinecircumstances as well, for patients who find themselves unable to

obtain treatment at their home OTP. This might be due to disruptionof a patient’s trip, or routine Sunday closure of the home OTP. (Morebackground can be found at the D-ATM website,http://datm.samhsa.gov/.) D-ATM provides an important case studyof how health information technology can be used to make health-care more safe, efficient, and cost-effective, and in a treatmentsetting where privacy concerns are paramount.

However, everyone who is part of the opioid treatment system,particularly OTP staff, administrators, and patients are time andtime again reminded of the kinds of policy issues that can emerge inthe wake of disaster, beyond the scope of D-ATM to address. Since 9-11 and Katrina, many large- and smaller-scale disasters havefollowed, each presenting their own challenges.

This Town Hall follows upon a similar Town Hall held at the lastAATOD conference. It will begin with a brief overview and statusreport on D-ATM under Phase III, including discussion of what hasbeen learned and what improvements have been made. Some repre-sentatives from OTPs currently implementing D-ATM will describetheir experiences in implementing the system, including issuesrelated to doing so in a corporate environment. Suggestions andquestions about the system and implementation are welcome, but itis hoped the Town Hall will also provide the opportunity for opendiscussion of the kinds of disaster preparedness and continuity ofcare issues that OTPs and their patients have encountered in real-life situations, whether due to widespread disasters or more routineservice disruptions. For instance, how have programs dealt withreimbursement issues or differences in dosing practices, when facedwith unfamiliar patients from other programs? What planning is inplace in terms of treating physically disabled patients, whether ornot D-ATM is available? Are referral systems lined up before they areneeded?

These are complicated issues and it is hoped this Town Hall willprovide one means to continue a dialogue among the many membersof the treatment community toward identifying which issues stillneed attention and who can best address them. Representatives ofSAMHSA/CSAT and other Federal and State agencies, members ofthe D-ATM Steering Committee, and program directors, patients andstaff who have had experience in working with D-ATM or in dealingwith disaster first-hand, are especially encouraged to attend.


The Policy Maker’s Luncheon on Monday, October25, 2010 is supported through a grant from Bendiner& Schlesinger, Inc.


MIDDLE PLENARY SESSION

8:45 a.m.–10:15 a.m.

Addiction, Pharmacology and the Criminal JusticeSystem: What are the Challenges to Expanding theUse of Pharmacologic Treatment Interventions forOpioid Dependent Individuals Under theJurisdiction of the Criminal Justice System?

Moderators:

Melody Heaps, President Emeritus, Treatment Alternatives forSafer Communities, Chicago, IL

West Huddleston, President, National Association of Drug CourtProfessionals, Alexandria, VA

Scott Chavez, Vice President, National Commission onCorrectional Healthcare, Chicago, IL

Dawn Bushma, LCSW, CADC, Senior US Probation Officer, USProbation Office, Chicago, IL (invited)

This plenary will be moderated by Melody Heaps, President Emer-itus, Treatment Alternatives for Safer Communities. Despite the factthat science has confirmed that addiction is a brain disease and nota question of lack of will power or moral failure, certain publicsectors have been resistant to using medication-assisted treatment.In particular, the criminal justice system has resisted, and in somecases prohibited the use of such treatment for addicted individuals.This plenary will explore the reasons behind such resistance, discussmodels of pharmacological treatments within the justice system, thechallenges treatment systems face in working with the criminaljustice system, and the future of medication-assisted treatment inthe criminal justice system.

10:30 a.m.–12:00 p.m.

WORKSHOP SESSIONS

C1 Alcohol Abuse inMethadone Treatment:Understanding and Addressing a Serious ProblemAllan J. Cohen, MA, Bay Area Addiction, Research andTreatment, Inc. (BAART), Los Angeles, CA

Daniel D. George, MPH, Matrix Institute on Addictions, LosAngeles, CA

Alcohol abuse in methadone maintained patients has proven to beamong the most costly and difficult problems to successfully addressand treat in the opioid treatment program. The costs of this problem

in terms of patient mortality, poor treatment outcomes, staff andprogram resources and negative community impact are enormous.

This workshop will present an overview of the problem of alcoholabuse in methadone maintained patient populations including areview of past and current research on this issue. We will explore anarray of clinical and programmatic issues related to alcohol abuseand discuss treatment options.

* Note: Basic Track

C2 AnAnalysis of Opioid-AddictedMedicaidPatients in Baltimore CityGregory C. Warren, MA, Baltimore Substance Abuse Systems,Inc., Baltimore, MD

Utilizing a coordinated public health response Buprenorphinemedication and innovative clinical and financial processes havebeen created to improve access and treatment outcomes for heroinaddicts in Baltimore. There will be three areas of discussion in theworkshop. First, critical lessons learned in how to establish abuprenorphine induction and stabilization continuum of care will bediscussed. Organizational change and new interagency partnershipsneeded to be forged to address the cultural, regulatory and financialbarriers which needed to be overcome. Finally, the presenter willshare Baltimore’s outcomes and preliminary research findings andwhether these changes achieved savings in health care utilization.

C3 TheGeorgia Strategy for StigmaReductionJonathan Connell, MA, Private Clinic, Albany, GA

Stacey Pearce, BS, GPA Treatment of Macon, Inc., Macon, GA

Joelyn Alfred, MS, Opioid Treatment Providers of Georgia,Norcross, GA

For years, treatment providers quietly provided treatment withoutconfronting the stigma in our communities. This presentation isdesigned to demonstrate the process Opioid Treatment Providers ofGeorgia went through to confront the stigma within the state ofGeorgia associated with Medication Assisted Treatment. Presenterswill discuss the collaborative process undertaken in developing thevideo “Exploring the World of Opioid Dependence” and how it ispresently being utilized in education and stigma reduction efforts. Inaddition, information will be provided on how to develop a compre-hensive plan for stigma reduction including planning for aMethadone Treatment Awareness Day.

C4 Improving Access andRetention in TreatmentKimberly Johnson, MBA, University of Wisconsin, Madison, WI

This workshop will share results of a year-long project that involved30 agencies working together to improve access to and retention intreatment using the NIATx model of process improvement. Bymaking simple changes like decreasing paper work, reorganizinggroup times, staffing for intake and accelerating dosing, these thirtyagencies reduced wait times, reduced no shows, improved group

Conference Sessions

Tuesday, October 26, 2010

Tuesday Continental Breakfast sponsored byReckitt Benckiser Pharmaceuticals, Inc.


attendance and increased retention. We will share how they did itand discuss opportunities for programs that may be interested inparticipating in a future learning collaborative.

C5 Partneringwith Patients: Developing anEffective PeerMentoring ProgramRobert C. Lambert, MA, Program Director, ConnecticutCounseling Centers, Inc., Norwalk, CT

Kurt Kemmling, CMA, Director/Founder, CT Chapter NationalAlliance Medication Assisted Recovery (NAMA), Danbury, CT

This workshop will focus on the development, implementation andintegration of peer mentoring services within a methadone treat-ment program, with a specific focus on strengthening the thera-peutic alliance between the patient and the program. Potentialbenefits relating to patient outcomes and staff utilization manage-ment will be discussed. The presenters will focus on providing infor-mation the workshop participants will need to replicate all or part ofthe initiative at their own programs. One key area of focus will be thedevelopment and implementation of a training curriculum for thepeer mentors including a specific focus on co-occurring disorders.

1:30 p.m.–3:00 p.m.

WORKSHOP SESSIONS

D1 Addressing Smoking Cessation in OpioidTreatment ProgramsShadi Nahvi, MD, Albert Einstein College of Medicine, Bronx,NY

Michael Stein, MD, Brown University Program in Medicine,Providence, RI

Kimber Richter, PhD, University of Kansas Medical Center,Kansas City, KS

Tobacco is a major cause of excess mortality among persons withopioid dependence, yet smoking continues to be under addressed intreatment programs. This workshop will provide an overview of theproblem as well as best practices and strategies for addressingtobacco use in opioid treatment programs (OTPs). The workshop willpresent an overview of epidemiology, followed by a discussion ofevidence-based practices in smoking cessation and the most recentdata from clinical trials. Several existing models of smoking cessa-tion services in OTPs will be discussed, focusing on practical ways toincorporate smoking cessation services into existing programs.

* Note: Basic Track


D2 Buprenorphine Pilot Project withParolees in ILDona Howell, CRADC, Illinois Department of Corrections,Marion, IL

Janelle Prueter, CRADC, TASC, Chicago, IL

Arturo Valdez, CSADC, Heritage Alternative Systems, Chicago,IL

Illinois’ Sheridan Correctional Center Project has gained nationalattention for its comprehensive approach to reducing recidivismamong drug-involved offenders. Sheridan parolees were 15% lesslikely to be rearrested for a new crime and 40% less likely to returnto prison for a new crime or technical violation.

Success rates for parolees with a history of opiate dependence havelagged behind those for the population as a whole. To address thisdisparity in outcomes, the Illinois Department of Corrections and itspartners are implementing a pilot project that will integrate medica-tion-assisted treatment into the continuum of care for parolees.

D3 National Drug and Alcohol Policy:2010 andBeyondPaul Samuels, JD, Legal Action Center, New York, NY

Gabrielle de la Gueronniere, JD, Legal Action Center,Washington, DC

Dan Belnap, JD, Legal Action Center, Washington, DC

Now is a time of tremendous opportunity for improving the federalresponse to drug and alcohol addiction. The federal healthcarereform law has strong coverage for addiction treatment. Newprograms and proposals at key federal agencies have the potential tosignificantly impact the treatment delivery system, and increasedcoverage for critical drug and alcohol-related services means morepeople in need of treatment will be able to access it. This workshopwill discuss these federal developments for addiction treatment,what it means for medication-assisted treatment specifically, andthe opportunities available for improving federal policy movingforward.

16

7:00 p.m.–9:30 p.m.

Introduction to the Awards Program

Please join us for the centerpiece of our Conference, a movingtribute to those individuals who have been nominated and selectedby their peers for extraordinary service in the opioid treatmentcommunity. These successful Award recipients have devoted them-selves to improving the lives of patients in our treatment system. Dr.Vincent Dole and Dr. Marie Nyswander were the first recipients ofthis Award in 1983. The Association has been responsible forbestowing this honor since the first Regional Conference of 1984 inNew York.

The 2010 American Association for the Treatment of OpioidDependence National Conference recognizes outstanding contri-butions to opioid treatment by honoring the following individualswith the Nyswander/Dole Award.

Miriam Ochshorn Adelson, MD Nevada

Dr. Adelson’s medication-assisted treatment experience began in1968 when she was sent by the Ministry of Health in Israel to workwith Dr. Mary Jeanne Kreek in New York. In 1993, she founded asubstance abuse treatment and research clinic in Israel thatprovides methadone maintenance treatment, and in 2000, sheopened a clinic in Las Vegas, Nevada. Dr. Adelson’s Las Vegas clinic isan outstanding research and treatment clinic that provides care andcontinues her long history of research concerning medication-assisted treatment. She continues to perform research, includingtreatment outcome evaluation studies, studies of relationship ofmethadone dose with serum levels, and collaborative researchstudies of human molecular genetics related to opioid addiction andtreatment.

Lawrence S. Brown, Jr., MD New York

Dr. Brown’s professional career is rooted at Addiction Research andTreatment Corporation based in Brooklyn, where he remains achampion of comprehensive treatment of opioid addiction. He didpioneering work in pharmacotherapy interventions such as LAAMand Buprenorphine and was at the vanguard of introducing HIVtreatment and prevention into ARTC’s opioid treatment programs.He spent two terms as President of the American Society of Addic-tion Medicine and is a powerful advocate of pharmacotherapy in thetreatment of addiction. Dr. Brown freely shares his expertise withtreatment providers and with regulators at the state and federallevel. He is as willing to listen as he is to offer his own view, alwaysfocusing on what is best for the patient.

Gregory Carlson Minnesota

In over 40 years as a medication-assisted treatment professional, Mr.Carlson has worked to set the standard for patient-oriented care in afield where much has changed. He began collecting and using datato determine how it influenced patient care in 1973 when this was

D4 MAT for Older Adults: SpecializedStrategies toMeet UniqueNeedsFran Schnadig, LCSW, PEER Services, Inc., Evanston, IL

Katrina Humphreys, LSW, PEER Services, Inc., Evanston,IL

Older adults who are addicted to drugs are being recognizedas an at-risk, under-identified and under-served population.MAT programs are working to identify new strategies to meetthe unique treatment requirements of this ever-increasingpopulation.

In responding to these needs, PEER Services has developedan evidence-based addiction treatment model whichaddresses:

• Unique stressors and losses of this population• Helping older adults increase positive self-caretakingbehaviors

• Communication problems and solutions for older adults andtheir families

• The specialized, evidence-based psychosocial treatmentapproach needed to meet the needs of older adultpatients—individual and group treatment modalities

D5 Partnershipwith the Patient:Key Interventions to Enhance RecoveryAlexander Kantchelov, MD, The Kantchelov Clinic, Sofia,Bulgaria

Tsvetana Stoykova, MA, The Kantchelov Clinic, Sofia,Bulgaria

Alexander Belchev, MD, The Kantchelov Clinic, Sofia,Bulgaria

Partnership with patients is seen as a basic philosophy, astyle of interaction, and an essential position and attitude ofstaff and institution. This workshop provides a model forspecific interventions, implemented at key points in theprocess of treatment-assisted recovery. Ways to develop part-nership at different levels—assessment and case formula-tion, engaging the patient in a collaborative effort towardchange, participation in the therapeutic process, definingand working together to achieve shared treatment goals—areexplored. The traditional TTT concept (Treatment—Therapy—Techniques) has evolved to promote a new model -PPP (Partnership—Progress—Process of Recovery).

The International Luncheon on Tuesday,October 26, 2010 is supported through grantsfrom Colonial Management Group, LP, andBollinger, Inc.

Conference Sessions


Awards Program



not the standard of care. Through direct patient care, managingmedication-assisted treatment programs, educating clinical andother staff at programs, and research, Mr. Carlson has demonstratedhis commitment to the field. His level of dedication has elevated himto be the go-to person in Minnesota for methadone related issues;providing assistance to new programs, local communities and regula-tory agency staff. He believes care should be about the patients andeveryone should work towards that goal.

Sergey Dvoryak, MD Ukraine

In 1999, Dr. Dvoryak became a Hubert H. Humphrey Drug AbuseResearch Fellow at Johns Hopkins University in Maryland. Thisopportunity led Dr. Dvoryak to a perspective of substance abuse as apublic health issue, which should be prioritized in accordance withits impact on society. Upon his return to his native Ukraine, Dr.Dvoryak worked to start both buprenorphine treatment andmethadone treatment to address the growing opioid use problem. Heis currently working to create a system of monitoring and evaluationof substance abuse treatment in the Ukraine, while providing educa-tion to other professionals about the importance of substance abusetreatment to public health.

Penny Hall, RPh Georgia

During her years as a retail pharmacist, Ms. Hall came to see addic-tion from a different perspective before she began to work in thefield. She witnessed countless patients receive addictive medicationthat might not have been necessary. Answering an ad for a part-timepharmacist she was exposed to methadone treatment, inspiring herto become a Sponsor of her own clinic in 1991. During her work inthe field, Penny was one of the founders of the Georgia methadoneproviders group, was the first AATOD delegate for the state ofGeorgia, has worked to mitigate the Georgia Board of Pharmacy’srestrictive regulations on narcotic treatment programs, and was theimpetus behind the creation of Methadone Treatment AwarenessDay in the Georgia House of Representatives.

Roland C. Lamb, MAOM Pennsylvania

Throughout his career as a provider, administrator and currentDirector of the Office of Addiction Services in Philadelphia, Mr.Lamb has remained an outspoken advocate for medication-assistedtreatment. He continues to wage a campaign to address communityopposition and stigma to opioid treatment. He supported, advocatedfor and funded a program that allows the methadone maintainedperson to continue in treatment while incarcerated in the Philadel-phia Prison System. Mr. Lamb also encourages patients to becomemore active in their treatment and develop self advocacy skills toinfluence public policy. He also formed a Collaborative comprised ofmedication-assisted treatment providers, regulators and othergovernment officials to improve communication and standards ofcare within medication-assisted treatment.

Peter William Lee, MA Vermont

Mr. Lee was Vermont’s first state employee to begin publicly advo-cating for medication-assisted treatment in the mid 1990s. At thattime, this position was strongly opposed by his superiors and thehighest ranking elected officials. At some risk to his career in stategovernment, he assisted in organizing proponents of methadonetreatment and began educating Legislators and others regarding thebenefits of this treatment. In 2002, Mr. Lee was successful andVermont’s first methadone clinic opened. Since that time, Mr. Leehas worked to grow the number of clinics to five throughout thestate. Mr. Lee has also been invaluable in increasing the number ofphysicians who are trained to provide office-based opioid treatmentutilizing buprenorphine.

John J. McCarthy, MD California

During his 30 years in the addiction field, Dr. McCarthy hasremained dedicated to providing quality treatment in a supportiveand respectful manner. He is appreciated for his passionate advocacyfor methadone patients and his commitment to integrating psychi-atric and other medical care into treatment. Dr. McCarthy works toeducate other professionals, is a practicing psychiatrist, a researcherand a member of numerous advisory committees. As a clinician-researcher, he understands the importance of using data to improvecare and has conducted numerous studies at his own clinic withoutexternal funding. During presentations he is able to speak to audi-ences with a wide range of educational background and has workedhard to change public policy from a punitive to a public healthmodel.

Theodora Binion Taylor, ThD Illinois

As a regulatory official, Dr. Binion Taylor has made great strides inintegrating substance abuse, mental health, domestic violence,HIV/AIDS services, and child welfare throughout treatment servicesin Illinois. She increased technology utilization throughout Illinois’treatment system to boost access to care and capture treatmentoutcome data. Dr. Binion Taylor supports training to assist providersin implementing evidence based treatment practices to enhance thequality of care for patients throughout Illinois. She is also a compas-sionate advocate for medication-assisted treatment and has foughttirelessly to reduce stigma and educate state leaders about theeffectiveness of this treatment modality. During the past two years,Dr. Binion Taylor has successfully ensured medication-assistedtreatment funding remains available, despite political pressure toreduce it.


Friend of the Field Award

The prestigious Friend of the Field Award was established by theAmerican Association for the Treatment of Opioid Dependence, Inc.Board of Directors. This award recognizes extraordinary contribu-tions to the field of opioid treatment by an individual or institutionwhose work, although not directly related to methadone treatment,has had a significant impact on our field. The 2010 Friend of theField Award has been awarded to:

C. West Huddleston

C. “West” Huddleston III, is the Chief Executive Officer of theNational Association of Drug Court Professionals (NADCP). Prior tobeing appointed CEO, Mr. Huddleston served as the first DeputyDirector and then Director of the National Drug Court Institute(NDCI) for nine years.

During his 11 years of service at NADCP, Mr. Huddleston has deliv-ered over 350 keynote speeches in 44 states and eight countries;authored 16 publications and briefs; developed and delivered 11national training curricula; briefed numerous state legislatures,testified before U.S. Congress, and international Parliaments; andhas been interviewed repeatedly by radio, television, and printmedia on topics related to alternative justice, alcohol and other drugabuse/dependence, drug policy, crime and public safety. Mr. Huddle-ston is regarded as a pioneer in drug courts and other alternativesentencing strategies having spent more than a decade providingvision and leadership throughout the world.

Prior to his work at NADCP/NDCI, Mr. Huddleston worked for eightyears as a board licensed clinician with misdemeanor and felonyoffenders at the county, state and federal levels. During this period,Mr. Huddleston worked throughout the Tennessee and Oklahomajustice systems to develop, implement and operate numerousoffender-specific, in-custody and community mental health andsubstance abuse treatment programs. Mr. Huddleston served as thedirector of two community corrections programs and as the interimdirector of a 125-bed pre-release correctional center.

Mr. Huddleston serves as an advisor and/or consultant to the U.S.Department of Justice (DOJ), U.S. Department of Transportation(DOT), U.S. Department of Health and Human Services (HHS), DrugEnforcement Administration (DEA), White House Office of NationalDrug Control Policy (ONDCP), United Nations Office of Drugs andCrime (UNODC), the Organization of American States (OAS) and asa distinguished faculty member of the National Judicial College.

Richard Lane/Robert HoldenPatient Advocacy Award

Richard Lane was a long-term heroin user who, upon release fromprison in 1967, was instrumental in establishing one of the Nation’sfirst methadone treatment programs. In 1974, he became the Execu-tive Director of Man Alive and later served as Vice President of theAmerican Methadone Treatment Association and as Vice Chairmanof the Governor’s Council on Alcohol and Drug Abuse in Maryland.Mr. Lane was a passionate advocate for methadone treatment and,by disclosing his own treatment experiences, provided inspiration topatients and colleagues alike.

Robert Holden was also a recovering heroin user, who later becamethe Director of PIDARC, an outpatient methadone treatmentprogram in the District of Columbia. He later served as the VicePresident of the American Association for the Treatment of OpioidDependence, succeeding Richard Lane’s term of office. This awardwas established in 1995 and recognizes extraordinary achievementsin patient advocacy.

Lisa Mojer-Torres, JD

Ms. Torres’ contributions, in her community and nationally, have hadan immense impact on awareness of medication-assisted treatmentand recovery. She is a tireless advocate for the dignity and rights ofpeople seeking care and in long-term recovery from addictionherself. Ms. Torres is currently the Consumer and Recovery Advocatefor New Jersey’s Division of Addiction Services and through this posi-tion works to bring the voices of people receiving services into allaspects of the Division’s activities. She has developed and presentedtrainings to the public that integrate her personal recovery experi-ences with the need for transformation of systems of care centeredon the rights and needs of individuals. She sits on many recoveryoriented committees, boards, and has held multiple national advi-sory board positions.

The 2010 Awards Banquet issupported through a grant fromCovidien–Mallinckrodt.

Awards Program



WORKSHOP SESSIONS

8:00 a.m.–9:30 a.m.

E1 Building Effective Therapeutic PartnershipsWithin Opioid Agonist TreatmentRobert C. Lambert, MA, Program Director, ConnecticutCounseling Centers, Inc., Norwalk, CT

Samuel R. Segal, MA, Director of Clinical Services, ConnecticutCounseling Centers, Inc., Waterbury, CT

Research indicates that the quality of the therapeutic relationshiphas a greater effect on patient retention and outcomes then thespecific counseling approach used. This “basic track” workshop willfocus on the essential fundamental counseling skill of forming andmaintaining the therapeutic relationship and the unique challengesinvolved in enhancing the therapeutic alliance with medication-assisted patients within the clinical setting. A key area of focus willbe counselor expectancy as a therapeutic factor. Boundary issuesspecific to the counselor in recovery will also be explored. Thepresenters will discuss methods to enhance the quality of the thera-peutic alliance.

* Note: Basic Track

E2 Using Data From the REMASStudy to AssistCounselors in Promoting Sexual Risk ReductionDonald Calsyn, PhD, Alcohol & Drug Abuse Institute, Universityof Washington, Seattle, WA

Robert Sterling, PhD, Jefferson Medical College, ThomasJefferson University, Philadelphia, PA

Stephen Weinstein, PhD, Jefferson Medical College, ThomasJefferson University, Philadelphia, PA

Findings from the Real Men Are Safe (REMAS) study will bepresented with an emphasis on results concerning engaging in sexunder the influence of drugs or alcohol. Suggestions about how find-ings from REMAS can be integrated into counseling sessions will bepresented. Despite the REMAS intervention being associated withsexual risk reduction and identified by the CDC as a promisingevidenced based HIV prevention intervention, few programs areusing REMAS materials.

Possible reasons for low adoption will be proposed and attendeeswill be led in a discussion of what would be needed to increase adop-tion of REMAS.

E3 PCSS-MentoringNetwork for OTPs: Safe UseofMethadone andBuprenorphineAndrew Saxon, MD, University of Washington, Seattle, WA

Gavin Bart, MD, Director of the Division of Addiction Medicineat Hennepin County Medical Center, Minneapolis, MN

Trusandra Taylor, MD, Medical Director, JEVS Human Services,Philadelphia, PA

This workshop describes the Physician Clinical Support Systems(PCSS) for Buprenorphine and Methadone, two relatedSAMHSA/CSAT funded networks of mentors who provide educationand support to clinicians prescribing buprenorphine and/ormethadone. The workshop offers an overview of the PCSS, describesits website, guidances and other resources, and discusses the policyimplications of this peer education strategy for OTPs and beyond.

E4 Can YouWatchMyKidsWhile I GetMedicated?Removing Barriers to TreatmentJeneane Burke, MSN, Thomas Jefferson University,Philadelphia, PA

Colleen Maguire, MHS, Thomas Jefferson University,Philadelphia, PA

The majority of female patients receiving MAT are single motherswith few supports. Lack of safe childcare is a major barrier toentering, engaging and/or remaining in treatment. The presenterswill share evidence on the need for childcare during MAT, benefits ofan on-site service and elements of Women’s Centered Treatment.They will describe their clinic’s Parent Child Center (PCC): staffing,funding, infection control measures, developmentally appropriateprogramming, assessment/referral of at risk children, communica-tion from PCC to the treatment team, acclimation of children to thePCC and how the PCC is linked into the parents’ treatment program.

E5 Innovative Group Treatment in an OutpatientOpioid Replacement TherapyElizabeth Bredin, LICSW, Program Director, Bay Cove TreatmentCenter, Boston, MA

Julia Carlson, LICSW, Senior Clinician, Bay Cove TreatmentCenter, Boston, MA

The Bay Cove Treatment Center is a clinically-oriented methadoneprogram treating dual-diagnosed patients. The treatment contractincludes one individual and at least one group session weekly, dailymethadone dosing, and random bi-weekly swabs. Focusing on short-term, goal-oriented 12-16 week groups, we redesigned the programto achieve the following goals:

• Increase group attendance and cohesiveness• Promote measurable life skills• Match group experience to specific patient needs• Decrease relapse• Introduce self-assessment form on group experience to evaluatepositive behavioral change and increased life skills.

Conference Sessions

Wednesday, October 27, 2010


9:45 a.m.–11:15 a.m.

F1 Linking Patientswith Communities ofRecoveryStephen Gumbley, MA, Co-Director, New England ATTC,Providence, RI

Walter Ginter, CMA, Medication-Assisted Recovery ServicesProject (MARS), Bronx, NY

Dona Dmitrovic, MHS, Assistant Director, The RASE Project,Harrisburg, PA

Faces & Voices of Recovery presents this workshop where you willlearn how to articulate a definition of recovery and medication-assisted recovery and how to apply recovery management principlesfor people using medication in their recovery. It is very important tolink patients with critical recovery support services and you willlearn about the successes and challenges in developing effectiverecovery models. Find out about the ways that your program can helpyour patients connect with communities of recovery using the expe-riences of the MARS and RASE projects that assist people usingmethadone and suboxone in their recovery.

* Note: Basic Track

F2 Why is the Role of the Professional NurseESSENTIAL in Addiction Treatment?Deborah Egel, JD, Office of Alcoholism and Substance AbuseServices, New York, NY

Carolyn Drennan, MA, Beth Israel Medical Center-MMTP, NewYork, NY

Colleen Corte, PhD, University of Illinois at Chicago, College ofNursing, Chicago, IL

Nurses care for individuals across the lifespan and across thecontinuum of health care settings. All professional nurses, regard-less of specialty are needed for the prevention, treatment, and reha-bilitation critical in meeting the goal of reducing substance use andits related health and social consequences. This presentation willdiscuss the importance of addiction nursing to providers, how NewYork has valued their nurses and created the Nurse Advisory Panel,and how a specific program has defined the nursing role as essentialand the resulting benefits for the Opioid Treatment Programpatients.

F3 Are YouReady—Really? SpecialConsiderations for Opioid Treatment Providers—PreparingNow for theNext DisasterRoye Brown, Program Sponsor and Administrative Director,Choices of Louisiana, Inc., Alexandria, LA

Nicholas Reuter, MPH, Senior Public Health Advisor,SAMHSA/CSAT/DPT, Rockville, MD

Brian McKernan, Technical Assistance Manager, SAMHSA’sDTAC (Disaster Technical Assistance Center), ClintonTownship, MI

Disasters—widespread or local, manmade or natural—can be espe-cially catastrophic for opioid treatment programs (OTPs) and otherproviders. OTPs have additional responsibilities to ensure patienthealth and safety by doing all possible to help patients’ uninter-rupted treatment. This workshop will provide an overview of behav-ioral health and opioid treatment—specific issues related todisaster preparedness; and information on the resources and toolsavailable now to help OTPs ensure they are as “disaster-ready aspossible.” Presenters will challenge OTPs to assess their prepared-ness for the next unexpected event, from terrorist attacks toinfluenza pandemics.


F4 Clinical Supervisors in Opioid TreatmentSettings:What are Their Needs?Monica A. Joseph, PhD, Addiction Research and TreatmentCorporation, Brooklyn, NY

Virginia Lambert, LCSW-R, Addiction Research and TreatmentCorporation, Brooklyn, NY

Supervisors who are experiencing high levels of job strain may alsobe having difficulty carrying out expected job functions includingclinical supervision. Without targeted clinical supervision, directcare practitioners’ professional skills development and patients’treatment outcomes can be impacted. While job redesign might notbe an option, enhancing supervisory expertise through the adoptionof formal supervisory models may decrease perceived job stress. Thisworkshop examines the systematic application of Stoltenberg,McNeil and Delworth’s Integrated Developmental Model of clinicalsupervision to assess, guide, challenge and support clinical supervi-sors across the three stages of professional counselor development.Perceived supervisory effectiveness is also assessed.

Conference Sessions

Wednesday, October 27, 2010


F5 Using Patient Chart Audits to ImproveCounselor Performance and Enhance Patient CareNancy Aiken, PhD, CHANA, Baltimore, MD

Meg Stoltzfus, LCPC, REACH Mobile Health Services, Baltimore,MD

As part of the quality assurance measures at R.E.A.C.H. MobileHealth Services, a program of the Institutes for Behavior Resources,Inc., over 20 quarterly patient chart audits were conducted during aspan of five years. This presentation, designed for clinical supervi-sors, program directors and staff involved in quality assurance proce-dures will include:

• Discussion on how to develop minimal standards for patient chartaudits,

• Guidance for evaluation of competencies consistent with a staffdevelopment program, and

• Examples of how audits can be utilized to guide allocation oftraining resources for clinical and medical staff.

CLOSING PLENARY SESSION

11:30 a.m.–12:45 p.m.

The Partnership of the Field and the FederalGovernment: The Expansion of Healthcare ReformandAccess to Quality Care

Speakers:

Howard Koh, MD, Assistant Secretary for Health, U.S.Department of Health and Human Services, Washington, DC(Invited)

Mark W. Parrino, MPA, President, American Association for theTreatment of Opioid Dependence, Inc., New York, NY

Susan McKnight, MPH, Program Coordinator, Lake CountyHealth Department, Waukegan, IL

AATOD is honored to have Dr. Howard Koh, Assistant Secretary forHealth, Department of Health and Human Services (Invited), towrap up the 2010 Conference in Chicago. Dr. Koh will discuss theimplementation of health care reform and the integration of addic-tion treatment services and primary health care.

of the year. Nearby the Cultural Center is the Art Institute, a magnif-icent museum where an endless number of art collections are ondisplay, including the largest collection of Impressionist and Post-Impressionist paintings in the world. The historic Grant Park andnewerMillennium Park, both stretching from Michigan Avenue tothe Lake Front are excellent places to sit and relax or take a stroll.Just to the south is theMuseum Campus, which lay the FieldMuseum of Natural History, the Shedd Aquarium and the AdlerPlanetarium. North Michigan Avenue, which includes the areaknown as the Magnificent Mile, is dominated by high end shops,luxury hotels and fancy restaurants.

Other sites and attractions in this area include theWrigleyBuilding, Tribune Tower,Water Tower Place, Navy Pier, and theJohn Hancock Center, which is the 6th tallest building in thecountry. Check out wonderful views of the city from its open sky deck

on the 94th floor. The hip River North neighborhood, just northwestof the Loop, is an area known for its numerous art galleries, restau-rants and nightclubs for tourists to enjoy. One of the more popularneighborhoods north of downtown is Lincoln Park. It is one of themore affluent areas in Chicago with its elegant homes and mansionsand trendy establishments. Its namesake park, the largest park inChicago, is home to the Lincoln Park Zoo, one of only three freeadmission zoos in the country and the Chicago History Museum.Farther north in the Lakeview neighborhood, is the Boystown areawhich is considered the heart of Chicago’s LGBT community. TheCenter on Halstead is the Midwest’s largest community and culturalcenter serving the lesbian, gay, bisexual and transgender community.

The Windy City


What comes to mind when you think of ‘CHICAGO’? Do you visualizebreathtaking skylines along Lake Michigan, “L” trains and a bustlingMichigan Ave? Famous public figures like Oprah Winfrey, MichaelJordan or President Barack Obama? Iconic sports teams such as theBears or Cubs? Perhaps dubious historical figures like the gangsterAl Capone? Or maybe you think of its colorful political landscape?While it’s true that all of those things are a part of Chicago, the cityhas numerous other treasures that can be explored during your freetime while attending the 2010 AATOD National Conference.

Chicago is a city deeply rooted in history, cultural diversity andarchitectural richness. The best way to experience this is by visitingsome of its many distinctive neighborhoods. With “L” trains, metratrains, buses and taxis easily accessible near the Hilton Chicago—the site of the Conference—-you won’t have any trouble traveling tomost areas. The Hilton Chicago itself is located in an area just southof the Loop, which has many interesting sites just within walkingdistance. In the most immediate area by the hotel, soak in livelyblues music across the street at the Buddy Guys Legends club or eatat one of the several mouth watering restaurants and be entertainedat the Jazz Showcase in the nearby Printers Row neighborhood.

The Loop is named for the center part of downtown in whichelevated “L” train tracks encircle the area above. A stroll downhistoric State Street provides for affordable shopping opportunitiesand for visiting several landmark buildings, including the beautifulHarold Washington Library and the Chicago Theater, with itsfamous six stories high vertical C-H-I-C-A-G-O marquee. The FordCenter for the Performing Arts, the Cadillac Palace Theater, theBank of America Theater and the Goodman Theater all are a partof Broadway in Chicago.

Michigan Avenue and the Lakefront lie just east of the Loop. Forthose brand new to the city, one of the best places to visit is theChicago Cultural Center, which is a place where you can enjoy freeart exhibitions, musical performances and special lectures every day


And though it will not be baseball season in late October, you wouldbe wise to check out the historicWrigley Field ballpark, home of theChicago Cubs. For other entertainment, drop in to see the BlueMan Group, the hilarious, vaudeville performance troupe that ishaving an open-ended run at the Briar Street Theater.

In theWest Loop area, you will find the tallest building in NorthAmerica, theWillis (Sears) Tower. Take in breathtaking views ofChicago from its 103rd floor sky deck. Parts of the near West Sidehave been transformed into a neighborhood characterized by lofts,boutiques and restaurants. One of the highlights of this area to see is

Harpo Studios, home of theOprah Winfrey Show, whichis near the neighborhoodknown as Greek Town. Othernotable attractions onChicago’s west side includethe United Center (home ofthe Bulls and Blackhawks)and the Jane Addams Hull-House Museum which is inthe Little Italy neighbor-hood. A hidden treasure on

Chicago’s west side is the Garfield Park Conservatory, one of thelargest conservatories in the United States. Further south west, isthe colorful Pilsen neighborhood, home to the largest Mexican-American community in the Midwest as well as the NationalMuseum of Mexican Art.

Not to be outdone, Chicago’s south side is steeped in rich history andhas plenty of attractions. One of them is the charming China Townarea with plenty of specialty shops and ethnic restaurantsthroughout the neighborhood. Not far from China Town is U.S.Cellular Field, home of the Chicago White Sox baseball team. Oneof the more diverse and unique neighborhoods in Chicago is theHyde Park-South Kenwood, home to the University of Chicago andtheMuseum of Science and Industry. Some of the lesser knowntreasures in this community include the Oriental Institute, whichdocuments the history and culture of the Middle East, the OsakaJapanese Garden, a beautiful nature sanctuary in Jackson Park,the iconic Robie House, and the Du Sable Museum of AfricanAmerican History. And of course, S. Kenwood is the home of Presi-dent Barack Obama.

As you can see, there’s plenty to do in Chicago in between beingenlightened by the research and ideas presented at the Conference!

For a detailed description, please visit the AATODwebsite (www.aatod.org).

Submitted by Tamika Whitehead, 2010 AATOD National ConferenceHospitality Chair

Hotel Information

Hilton Chicago720 South Michigan AvenueChicago, IL 60605312-922-4400Fax: 312-922-5240

Sleeping room rates have been reserved for attendees at a confer-ence rate of $269 single, $289 double occupancy in a standard room,many of the double occupancy rooms blocked for the AATOD confer-ence have both two beds and two bathrooms. This reduced rate isavailable until October 1, 2010, subject to availability. Reservationrequests received after the cut-off date of October 1, 2010 will bebased on availability at the Hotel’s prevailing rates.

To reserve a room at the group rate, contact the hotel directly bycalling their reservation line at 1-877-865-5320. Please be sure toreference the American Association for the Treatment of OpioidDependence or AATOD National Conference. Reservations can alsobe made on-line through the AATOD website by clicking on the HotelReservations Link.

Ground Transportation

Both airports offer plentiful taxi service to downtown and thesuburbs. Rates range from $30–$50 from O’Hare and $28–$32 fromMidway. Rates vary based on travel time.

GO Airport Express provides shared ride services to alldowntown/suburban hotels and many businesses. Rates are listedbelow, visit www.airportexpress.com/discounts.html for discounts orcoupons.

O’Hare Airport PER PERSON Midway Airport PER PERSON

Single oneway $27.00 Oneway $22.00Single round trip $49.00 Round trip $39.00

Public transportation is also an option on CTA (Chicago TransitAuthority) from O’Hare Airport. The Blue line is a short walk fromthe Hilton and goes directly to O’Hare Airport for a fare of $2.25 eachway. Please visit www.transitchicago.com for more information.


Conference Contacts

Talley Management Group, Inc.Alexandra Springer, Meeting Manager19 Mantua RoadMount Royal, New Jersey 08061Phone: 856-423-3091Fax: 856-423-3420E-mail: [email protected]: www.aatod.org

Exhibit Sales

Sue Parker, Sales [email protected]

Continuing Education Credits

AATOD, Provider #1044, is approved as a provider for socialwork continuing education by the Association of Social WorkBoards (ASWB).

AATOD is an approved provider through the National Associa-tion of Alcoholism and Drug Abuse Counselors (NAADAC),Provider #000218.

AATOD is an approved provider through the State of CaliforniaBoard of Behavioral Science, Provider # 4101.

Application to award Continuing Education hours (CEHs) willbe submitted to IAODAPCA, Illinois Alcohol and other DrugAbuse Professional Certification Association, Inc.

This continuing nursing education activity will be submittedto the New York State Nurses Association, an accreditedapprover by the American Nurses Credentialing Center’sCommission on Accreditation.

Application to award Continuing Education hours (CEHs) alsowill be submitted to the National Board of Certified Coun-selors (NBCC).

Conference Information

HOW TO REGISTER:

Registration for the American Association for the Treatment ofOpioid Dependence, Inc. (AATOD) National Conference can be doneon-line by visiting the AATOD website at www.aatod.org or bycompleting the registration form on the inside back cover and faxingit to 856-423-3420 or by mailing it to:

AATOD 2010 National Conference Registrationc/o Talley Management Group, Inc.19 Mantua RoadMt. Royal, NJ 08061

If faxing your registration, DO NOT mail the original form, doing somay result in duplicate charges to your credit card! Should you haveany questions regarding conference registration please call 856-423-3091.

* Includes: Admission to Pre-Conference Sessions (excluding CMATraining Course and Clinicians Course), Welcome Reception, allPlenary Sessions, Workshops, daily continental breakfast, ExhibitorsNetworking Refreshment Break, and Awards Banquet.

There can be no conference registration fee splitting. Only onediscount per conference participant is allowed, including thepresenter’s discount.

Group Discounts do not apply for the following categories:

Single Day Registration (Does NOT include Awards Banquet) . . . . . . . . . . . $250.00

Clinicians Course (Includes Welcome Reception). . . . . . . . . . . . . . . . . . . . . $175.00

Additional Awards Banquet Tickets. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 75.00

Additional Welcome Reception Tickets . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 30.00

CME/CEH FeesThese fees are not included in full conference registration fee

Physicians/Physician Assistants/Pharmacists . . . . . . . . . . . . . . . . . . . . . . . $ 45.00

Nurses/Social Workers/Psychologists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 35.00

Counselors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 25.00

Special Needs

The American Association for the Treatment of Opioid Dependencewishes to take steps to ensure that no disabled person is excluded,denied services, segregated, or otherwise treated differently thanother individuals because of the absence of auxiliary aids andservices. If you require any auxiliary aids or services identified inthe Americans with Disabilities Act, please indicate so on yourregistration form.

Full Conference Registration * 1 person froman agency

2 or more froman agency, each

Standard Registration until September 17, 2010 $500.00 $465.00

On-Site October 23, 2010 $575.00 No Group DiscountApplies

Registration Info & Fees

Credit Card InformationCARD NUMBER EXPIRATION DATE

Use one form for each registrant. Photocopies of the form are acceptable. Pleaseregister on-line at www.aatod.org and click on the ON-LINE REGISTRATION link orcomplete the registration form.

You may now register two or more from an Agency through the AATOD website.

Contact Information: Please print. Bold fields will print on badge.

First Name MI Last Name

Name on Badge Affiliation

Position/Title Degree

Business Address

City State/Province Country Zip Code

Business Telephone Fax Number

E-Mail Address

Please check only the professional designation that applies:

�� Administrative/Management �� Policy�� Clinical/Medical �� Research�� Counseling �� Other (Please Specify)�� Funding/Evaluation ________________________________________

FULL CONFERENCE REGISTRATION:Includes Welcome Reception and Awards Banquet (check all that apply)

Pre-Registrationby September 17 On-Site Fee enclosed

�� One person from an agency $500 $575 $ ________

�� Two or more from an agency, each $465 $575 $ ________

�� Single Day (specify day below) $250 $250 $ ________

�� Sunday �� Monday �� Tuesday (Does not include Awards Banquet) �� Wednesday

�� Yes, I will be attending the Welcome Reception�� No, I will not attend the Welcome Reception�� Yes, I will be attending the Awards Banquet�� No, I will not attend the Awards Banquet�� Yes, I will be attending the Clinic Tours�� No, I will not attend the Clinic Tours

�� Clinicians Course $175 $ ________�� Additional Awards Banquet tickets $ 75 $ ________�� Welcome Reception tickets $ 30 $ ________

CME/CEH Fees (Not included in conference registration fee)

Please indicate the type of continuing education units you intend to seek:

�� Physicians �� Physician Assistants �� Pharmacists $45 $ ________

�� Nurses �� Social Workers �� Psychologists $35 $ ________

Social Worker License #_____________________ State of Licensure ________

�� Counselors $25 $ ________

TOTAL FEES $ ________

Register for the conference on-line at www.aatod.org or mail or fax the RegistrationForm with your payment in full to:

AATOD 2010 National Conference Registrationc/o Talley Management Group, Inc.19 Mantua RoadMt. Royal, New Jersey 08061Fax: 856-423-3420

Please indicate any special assistance required: ____________________________________________

________________________________________________________________________________________________________

PAYMENT INFORMATION:

�� Enclosed is payment by CHECK payable to the American Association for theTreatment of Opioid Dependence, Inc.

To assure prompt processing of your registration, please be sure to remit yourcheck in U.S. dollars and issued by a U.S. correspondent bank. Please check withyour local bank before processing payment. Each registrant is responsible forany and all bank charges. A $50.00 processing fee will be charged for checksreturned unpaid.

�� I wish to pay my fees by CREDIT CARDPlease note this charge will appear on your statement as “AATOD ConferenceRegistration”

�� Visa �� MasterCard �� American ExpressPlease provide card number and expiration date below.

Total fees to be charged $ _______________

Cardholder’s Signature ________________________________________________________________________

Registrations paid by credit card may be faxed to 856-423-3420. Please keep acopy of your fax confirmation for your record. If faxing, DO NOT mail the originalform; doing so may result in duplicate charges to your credit card! AATODreserves the right to charge the correct amount if different from the totalabove.

AATOD does not accept purchase orders as a form of payment.

CANCELLATION POLICYIf you must cancel your registration, the American Association for the Treat-ment of Opioid Dependence, Inc. Registration Department must receive allrequests in writing no later than September 17, 2010. All fees paid will bereturned less a $50.00 processing fee. There will be no refunds under anycircumstance after the September 17th deadline.

REPLACEMENT POLICYReplacements will only be processed when requests are received in writingprior to September 17, 2010. There will be NO replacements after that date.

Participation in this conference assumes knowledge and authorization of audioand/or video recording of portions of this conference.

Registration will be confirmed in writing within two weeks of receipt of payment. Ifyou do not receive confirmation by that time, please call 856-423-3091, option 3.

Registration Form

CONFERENCE REGISTRATION

Building Partnerships:Advancing Treatment & Recovery

October 23–27, 2010 • Hilton Chicago • Chicago, Illinois

19 Mantua RoadMt. Royal, New Jersey 08061www.aatod.org

Professionally Managed by

PRSRT STDUS POSTAGEPAIDKCMO 2257

chicago2o1o - aatod aatod... · chicago2o1o october 23 –27, ... 1 :30 a. m– 245 pc l os i ng p...

Documents